Zscaler Inc. (ZS)

The shares trade at $194.92, 71.30% above their 52-week high of $333.90 but 70.05% above the 52-week low of $114.63. The price sits above its 200-day average of $166.85 yet below the 50-day average of $208.44, a mixed picture that leaves the stock in a wide, unsettled range. Analysts remain constructive, with 36 of 47 ratings at Buy, while CleaRank's own rating is Hold, a more cautious reading than Wall Street's consensus.

The stock fell 13.40% over the past week and 16.60% over the past month, leaving the price 11.15% below its 20-day exponential average. Momentum has weakened with it: the 14-day RSI is 36.7, in the bearish zone, and the MACD line is negative. The decline has no company-specific cause attached to it in the reporting, so the move is best read as a shift in sentiment rather than a company-specific event. Over three months the stock is still up 9.17% and over six months up 33.35%, but the one-year return of 40.74% down shows how far it has retreated from its earlier highs.

Its reported earnings per share over the last 12 months are -$0.39, so the price-to-earnings ratio is not meaningful. The stock trades at 9.68 times sales, 27.4% above the sector median of 7.6. Investors are paying a premium for growth that has not yet reached the bottom line.

Of 47 analysts with a current rating, 36 rate the stock Buy or Strong Buy, 11 Hold and none Sell. Three months earlier 37 of 46 rated it Buy. Recent actions include Freedom Broker keeping its Buy rating on October 22, 2026, and DA Davidson starting coverage at Neutral on October 21, 2026. Insiders sold $123.1 million of stock across 59 sales over the last 18 months, with no open-market purchases. Those sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than purchases would.

The base case for the coming months is that the stock stays range-bound between its 200-day average and its 50-day average while the market weighs strong top-line growth against losses. Revenue is expected to grow 17.3% this fiscal year, and analysts expect EPS to rise 16.6% to $4.91, so the case for a recovery depends on those estimates holding. A reclaim of the 50-day average at $208.44 and then the 20-day EMA at $219.38 would show the selling has eased. Analysts' median 12-month target is $247.00, within a range of $164.75 to $298.00, but the stock's negative earnings and bearish momentum mean those targets depend on execution that has yet to show up in profits.

Support sits at the 200-day simple moving average of $166.85, the nearest level below the price, which the stock has held as a floor in its recent trend. Below it, the 52-week low of $114.63 marks the bottom of the past year's range and the level a sharper decline would test next. Resistance begins at the 50-day simple moving average of $208.44, the nearest level above the price and the first hurdle for any rebound. Above that, the 20-day exponential moving average of $219.38 would be the next level to reclaim, and the 52-week high of $333.90 sits far above the current price.